- Durable Goods Orders are set to rise in November, yet at a moderate pace in November.
- An underestimation of previous months implies a potential for another upside surprise.
- Vaccine news and the conclusive US elections may have also boosted long-term investment.
Winter has come early in the northern hemisphere – the winter wave of coronavirus has hit the US hard and caused the Federal Reserve to talk about a more moderate recovery. However, for long-term investment, the penultimate month of 2020 may have been upbeat.
Reflecting that slowdown – related to the virus and to the lack of additional federal stimulus – Retail Sales took a hit last month, falling by 1.1%. Jobless claims also missed estimated and showed a worrying increase.
Why Durables could beat expectations
Economists expect Durable Goods Orders to follow a similar path, with the headline rising by a moderate 0.6%, around half October's increase of 1.3%. The Nondefence ex-air component – aka "core of the core" is forecast to advance by 0.6% a slowdown from 0.8% beforehand.
However, there are two reasons to expect a better outcome rather than a weaker one. First, the chart above shows that core durables beat estimates in seven out of eight of the last releases, and met expectations in the sole exception. The consensus has been too downbeat, opening the door for another upside surprise.
The second reason is that durables reflect long-term investment – and that is based on expectations rather than the current situation. On November 9, Pfizer and BioNTech announced a high efficacy rate for their COVID-19 vaccine. On the following week, Moderna followed suit with a similar outcome.
Such upbeat developments may have pushed businesses to invest for the long-term, seeing the light at the end of the tunnel.
Another relief for markets came from the decisive US elections. While it took several days, the networks called the election for Joe Biden on November 7 – and President Donald Trump's attempts to overturn the results seemed improbable then as they look now, after a losing streak at the courts. The sense of relief probably contributed to calm.
If the assessment above is correct, there is room for an upside surprise and for the dollar to rise. A US economy that sees investment in the hard times is ready to surge once vaccines take their effect. A return to robust growth implies lower chances of the Federal Reserve buying more bonds.
In case the data meets estimates, markets would likely return to scrambling around the latest news, most notably the new covid strain. Positioning ahead of Christmas could overshadow any reaction to the figures.
In the unlikely case of an investment downfall, the dollar could be dragged lower on the expectation that the Fed increases its bond-buying scheme.
November's vaccine announcements are good reasons for Durable Goods Orders to beat estimates, boosting the dollar,
Information on these pages contains forward-looking statements that involve risks and uncertainties. Markets and instruments profiled on this page are for informational purposes only and should not in any way come across as a recommendation to buy or sell in these assets. You should do your own thorough research before making any investment decisions. FXStreet does not in any way guarantee that this information is free from mistakes, errors, or material misstatements. It also does not guarantee that this information is of a timely nature. Investing in Open Markets involves a great deal of risk, including the loss of all or a portion of your investment, as well as emotional distress. All risks, losses and costs associated with investing, including total loss of principal, are your responsibility. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of FXStreet nor its advertisers. The author will not be held responsible for information that is found at the end of links posted on this page.
If not otherwise explicitly mentioned in the body of the article, at the time of writing, the author has no position in any stock mentioned in this article and no business relationship with any company mentioned. The author has not received compensation for writing this article, other than from FXStreet.
FXStreet and the author do not provide personalized recommendations. The author makes no representations as to the accuracy, completeness, or suitability of this information. FXStreet and the author will not be liable for any errors, omissions or any losses, injuries or damages arising from this information and its display or use. Errors and omissions excepted.
The author and FXStreet are not registered investment advisors and nothing in this article is intended to be investment advice.